AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9631672 — intervention group
Group type: EXPERIMENTAL
Intervention: Home vaccination service for DTP/OPV/Hib
Number of subjects: 405
Study 9631672 — intervention group
Group type: COMPARATOR
Intervention: Control group for DTP/OPV/Hib
Number of subjects: 405
Study 9631672 — intervention group
Group type: EXPERIMENTAL
Intervention: Home vaccination service for MMR
Number of subjects: 405
Study 9631672 — intervention group
Group type: COMPARATOR
Intervention: Control group for MMR
Number of subjects: 405
Study 7705552 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate 2 g b.d.
Number of subjects: 16
Study 7705552 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 3300310 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of norfloxacin (600 mg twice daily)
Number of subjects: 0
Study 3300310 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of norfloxacin (800 mg)
Number of subjects: 0
Study 3300310 — intervention group
Group type: COMPARATOR
Intervention: Single-dose ampicillin (3.5 g)/probenecid (1.0 g)
Number of subjects: 0
Study 2123903 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior infarction with precordial ST segment depression (Group II)
Number of subjects: 583
Study 2123903 — intervention group
Group type: COMPARATOR
Intervention: Inferior infarction without precordial ST segment depression (Group III)
Number of subjects: 583
Study 1062553 — intervention group
Group type: EXPERIMENTAL
Intervention: Contoured toothbrush
Number of subjects: 78
Study 1062553 — intervention group
Group type: COMPARATOR
Intervention: Oral B toothbrush
Number of subjects: 78
Study 31899198 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling the same or older than chronological age
Number of subjects: 533
Study 30047786 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10‐20 mg)
Number of subjects: 30
Study 30047786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29246235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse or Auxiliary Nurse-Midwives (ANMs)
Number of subjects: 1051
Study 29246235 — intervention group
Group type: COMPARATOR
Intervention: Doctors
Number of subjects: 1051
Study 26292291 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV31 DNA load
Number of subjects: 530
Study 26292291 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial viral loads
Number of subjects: 530
Study 26292291 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in viral loads
Number of subjects: 530
Study 23097083 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure delinquent group condition
Number of subjects: 70
Study 23097083 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed group condition
Number of subjects: 70
Study 23097083 — intervention group
Group type: COMPARATOR
Intervention: Pure normative group condition
Number of subjects: 70
Study 21716274 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel regimen of 300 mg loading dose (LD) and 75 mg/day maintenance dose (MD) for 4 days
Number of subjects: 40
Study 21716274 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel regimen of 600 mg LD and 150 mg/day MD
Number of subjects: 40
Study 21716274 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel regimen of 75 mg/day MD
Number of subjects: 40
Study 21716274 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel regimen of 150 mg/day MD
Number of subjects: 40
Study 21716274 — intervention group
Group type: COMPARATOR
Intervention: Pooled analysis of CYP polymorphisms
Number of subjects: 40
Study 19648146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg once daily
Number of subjects: 3494
Study 19648146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg once daily
Number of subjects: 3494
Study 19648146 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (Control)
Number of subjects: 3494
Study 19648146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg and 150 mg
Number of subjects: 3494
Study 16729745 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low-volume infusion (10 cc of dye infused over 2.5 hours)
Number of subjects: 21
Study 16729745 — intervention group
Group type: COMPARATOR
Intervention: Intermittent high-volume bolus infusion (10 cc bolus of dye)
Number of subjects: 21
Study 15099614 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 15099614 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS mania-like factor items
Number of subjects: 0
Study 15099614 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS
Number of subjects: 0
Study 11754859 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-impregnated collagen fleeces (Septocoll); 3 fleeces applied locally
Number of subjects: 97
Study 11754859 — intervention group
Group type: COMPARATOR
Intervention: Control group (sacral drainage plus primary wound closure)
Number of subjects: 97
Study 9243208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic conjugated oestrogens 0.3 mg/day
Number of subjects: 27
Study 9243208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic conjugated oestrogens 0.625 mg/day
Number of subjects: 27
Study 9243208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic conjugated oestrogens 1.25 mg/day
Number of subjects: 27
Study 8298943 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 24
Study 3508764 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 0
Study 3508764 — intervention group
Group type: COMPARATOR
Intervention: 5 I.D.U.
Number of subjects: 0
Study 30403495 — intervention group
Group type: EXPERIMENTAL
Intervention: Webdia app intervention for 3 months with monthly feedback and adaptation of treatment
Number of subjects: 55
Study 30403495 — intervention group
Group type: COMPARATOR
Intervention: Control group (no app intervention)
Number of subjects: 55
Study 30403495 — intervention group
Group type: EXPERIMENTAL
Intervention: Webdia app intervention
Number of subjects: 55
Study 28558859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis
Number of subjects: 24
Study 28558859 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco
Number of subjects: 24
Study 28558859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24241260 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored pharmacist intervention
Number of subjects: 43
Study 24241260 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 21347905 — intervention group
Group type: EXPERIMENTAL
Intervention: Experientially-primed condition
Number of subjects: 63
Study 21347905 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-primed condition
Number of subjects: 63
Study 21347905 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 63
Study 18317243 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal (900 mg for 18 months)
Number of subjects: 257
Study 18317243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 17010858 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic acrylic IOL (BL27, Bausch & Lomb)
Number of subjects: 120
Study 17010858 — intervention group
Group type: COMPARATOR
Intervention: Hydrophobic acrylic IOL (AcrySof SA60AT, Alcon)
Number of subjects: 120
Study 16215013 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zinc/d in cherry syrup
Number of subjects: 38
Study 16215013 — intervention group
Group type: COMPARATOR
Intervention: Cherry syrup alone (placebo)
Number of subjects: 38
Study 10215647 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐966 (50 mg every day)
Number of subjects: 36
Study 10215647 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg t.i.d.)
Number of subjects: 36
Study 10215647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8845793 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic vaccination with Semliki forest virus (SFV) recombinant expressing SFV - PBj14 envelope protein
Number of subjects: 2
Study 8845793 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic vaccination with toxoid of alpha interferons
Number of subjects: 2
Study 1706607 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 recombinant gp160 vaccine (40 or 80 micrograms)
Number of subjects: 33
Study 1706607 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 recombinant gp160 vaccine (fourth immunization)
Number of subjects: 33
Study 1706607 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 recombinant gp160 vaccine
Number of subjects: 33
Study 389261 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 200
Study 389261 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 200
Study 30064953 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCU-CHEK Inform II displaying 'RR LO' reading
Number of subjects: 66
Study 30064953 — intervention group
Group type: COMPARATOR
Intervention: ACCU-CHEK Inform II displaying '32 mg/dL' reading
Number of subjects: 66
Study 27194176 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX (fluorouracil-oxaliplatin-folinic acid) combined with concurrent radiotherapy (41.4 Grays)
Number of subjects: 106
Study 27194176 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel combined with concurrent radiotherapy (41.4 Grays)
Number of subjects: 106
Study 24227768 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (32 mg/day i.m.)
Number of subjects: 7
Study 24227768 — intervention group
Group type: COMPARATOR
Intervention: Morphine (120 mg/day i.m.)
Number of subjects: 7
Study 22831286 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable puree-based drinks (FVPD) 200 mL daily for 6 weeks
Number of subjects: 39
Study 22831286 — intervention group
Group type: COMPARATOR
Intervention: Fruit-flavoured control
Number of subjects: 39
Study 20171695 — intervention group
Group type: EXPERIMENTAL
Intervention: BackStop (experimental group)
Number of subjects: 68
Study 20171695 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiretropulsion device)
Number of subjects: 68
Study 17368095 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level jaw-clenching
Number of subjects: 23
Study 17368095 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate injection
Number of subjects: 23
Study 17368095 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection
Number of subjects: 23
Study 16320148 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline walking speed reduction (0.10 m/s)
Number of subjects: 1388
Study 16320148 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking speed increase (0.10 m/s/yr)
Number of subjects: 1388
Study 12174518 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet drug triflusal (600 mg)
Number of subjects: 99
Study 12174518 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation for an INR of 2-3
Number of subjects: 99
Study 12174518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with anticoagulation (mean INR of 1.85)
Number of subjects: 99
Study 12174518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with anticoagulation (mean INR of 2.15)
Number of subjects: 99
Study 12174518 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (group C)
Number of subjects: 99
Study 10462363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 115
Study 10462363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 7793997 — intervention group
Group type: EXPERIMENTAL
Intervention: AO-90 (500-750 ml/day)
Number of subjects: 118
Study 7793997 — intervention group
Group type: COMPARATOR
Intervention: Commercial amino acid solution (600-800 ml/day)
Number of subjects: 118
Study 2358926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding hip screw (SHS) at 130 degrees
Number of subjects: 24
Study 2358926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding hip screw (SHS) at 135 degrees
Number of subjects: 24
Study 2358926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding hip screw (SHS) at 140 degrees
Number of subjects: 24
Study 2358926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding hip screw (SHS) at 145 degrees
Number of subjects: 24
Study 2358926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding hip screw (SHS) at 150 degrees
Number of subjects: 24
Study 2358926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact femur with SHS inserted
Number of subjects: 24
Study 2358926 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable two-part intertrochanteric fracture reduced with SHS
Number of subjects: 24
Study 2358926 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-part fracture with PMF reduced anatomically by a lag screw
Number of subjects: 24
Study 2358926 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-part fracture with PMF rotated 180 degrees and held by a lag screw
Number of subjects: 24
Study 2358926 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-part fracture with PMF discarded
Number of subjects: 24
Study 393386 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC at a dose of 200 mg/m2 iv on Days 1‐5 and cis‐dichlorodiammine‐platinum(II) at a dose of 40 mg/m2 iv on Days 1 and 4, repeated every 4 weeks (group A)
Number of subjects: 29
Study 393386 — intervention group
Group type: COMPARATOR
Intervention: DTIC at a dose of 200 mg/m2 iv on Days 1‐5 and cis‐dichlorodiammine‐platinum(II) at a dose of 40 mg/m2 iv on Days 1 and 4, repeated every 4 weeks, plus procarbazine at a dose of 75 mg/m2 orally daily on Days 1‐8 and vincristine at a dose of 1.4 mg/m2 iv on Day 1 (group B)
Number of subjects: 29
Study 30060681 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (CSI) alone
Number of subjects: 20
Study 30060681 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (CSI) with 3 weeks of immobilization
Number of subjects: 20
Study 31262544 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone orally
Number of subjects: 38
Study 31262544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 28077214 — intervention group
Group type: EXPERIMENTAL
Intervention: The Incredible Years (IY)
Number of subjects: 387
Study 25694068 — intervention group
Group type: EXPERIMENTAL
Intervention: Milled flaxseed (30 g/day)
Number of subjects: 110
Study 25694068 — intervention group
Group type: EXPERIMENTAL
Intervention: Milled flaxseed (30 g/day) + cholesterol-lowering medications (CLM)
Number of subjects: 110
Study 25694068 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 g whole wheat) + cholesterol-lowering medications (CLM)
Number of subjects: 110
Study 24345206 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurkers
Number of subjects: 0
Study 24345206 — intervention group
Group type: COMPARATOR
Intervention: Posters
Number of subjects: 0
Study 21689900 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 4 mg
Number of subjects: 200
Study 21689900 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 50 μg
Number of subjects: 200
Study 18925978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) B12 replacement therapy
Number of subjects: 28
Study 18925978 — intervention group
Group type: COMPARATOR
Intervention: Normal serum B12 levels (>300 pg/mL)
Number of subjects: 28
Study 17617282 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT)
Number of subjects: 79
Study 17617282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 14763531 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-operated PMMA vacuum mixing and delivery system
Number of subjects: 0
Study 14763531 — intervention group
Group type: COMPARATOR
Intervention: Manually powered industry standard
Number of subjects: 0
Study 11995670 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 200 microg
Number of subjects: 983
Study 11995670 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 400 microg
Number of subjects: 983
Study 11995670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 983
Study 9523927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2 mg, 4 mL)
Number of subjects: 44
Study 9523927 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 mL of nebulized normal saline)
Number of subjects: 44
Study 9523927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide
Number of subjects: 44
Study 9523927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 2039811 — intervention group
Group type: EXPERIMENTAL
Intervention: 49.2 mg pseudoephedrine (ACTIFED)
Number of subjects: 1
Study 2039811 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 1
Study 2039811 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.51 L mineral water
Number of subjects: 1
Study 2039811 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg bumetanide
Number of subjects: 1
Study 6301412 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% delta 9‐tetrahydrocannabinol (delta 9‐THC)
Number of subjects: 28
Study 6301412 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (light mineral oil)
Number of subjects: 28
Study 30663520 — intervention group
Group type: EXPERIMENTAL
Intervention: Subanaesthetic intravenous ketamine infusion
Number of subjects: 30
Study 29273594 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 0.8 mg combined with enalapril 10 mg
Number of subjects: 8384
Study 29273594 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg alone
Number of subjects: 8384
Study 26590016 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of normal saline injected into the knee joint of the experimental group.
Number of subjects: 40
Study 26590016 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 40
Study 25039738 — intervention group
Group type: COMPARATOR
Intervention: Telephone supervision (distant)
Number of subjects: 53
Study 25039738 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person after telephone consultation (immediately available)
Number of subjects: 53
Study 25039738 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person from the beginning of the simulation (direct)
Number of subjects: 53
Study 22898278 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific sublingual immunotherapy with dermatophagoides farinae drops
Number of subjects: 106
Study 22898278 — intervention group
Group type: COMPARATOR
Intervention: Standardized treatment alone (Control)
Number of subjects: 106
Study 20724562 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (6 g in 500 ml beverage)
Number of subjects: 9
Study 20724562 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 9
Study 18424200 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethylstarch 130/0.4 (median of 750 ml administered)
Number of subjects: 30
Study 18424200 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 30
Study 18424200 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethylstarch 130/0.4
Number of subjects: 30
Study 16186460 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational physical activities
Number of subjects: 681
Study 16186460 — intervention group
Group type: EXPERIMENTAL
Intervention: Back exercises
Number of subjects: 681
Study 12540643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (60 mg orally every 4 hours)
Number of subjects: 1650
Study 12540643 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate (intravenous according to institutional protocol)
Number of subjects: 1650
Study 10653212 — intervention group
Group type: EXPERIMENTAL
Intervention: biperiden (4 mg)
Number of subjects: 14
Study 10653212 — intervention group
Group type: EXPERIMENTAL
Intervention: trihexyphenidyl (5 mg)
Number of subjects: 14
Study 10653212 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 9435389 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatellier‐Adams technique (group I)
Number of subjects: 3
Study 9435389 — intervention group
Group type: EXPERIMENTAL
Intervention: Kenneth‐Johnson technique (group II)
Number of subjects: 3
Study 9435389 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossed canulated screws (group III)
Number of subjects: 3
Study 8447161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted live attenuated vaccine (two doses)
Number of subjects: 2
Study 8447161 — intervention group
Group type: COMPARATOR
Intervention: Whole-virus inactivated vaccine (one dose)
Number of subjects: 2
Study 2876451 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg/day)
Number of subjects: 150
Study 2876451 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (150 mg/day)
Number of subjects: 150
Study 31268610 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase 2 mg
Number of subjects: 48
Study 31268610 — intervention group
Group type: COMPARATOR
Intervention: Alteplase 1 mg
Number of subjects: 48
Study 30256784 — intervention group
Group type: EXPERIMENTAL
Intervention: SphygmoCor® CPV device used to assess carotid-femoral PWV
Number of subjects: 652
Study 30256784 — intervention group
Group type: EXPERIMENTAL
Intervention: SphygmoCor® CPV device used to obtain C‐SBP
Number of subjects: 652
Study 30256784 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression analyses for PWV and C‐SBP adjusted for age, sex, and race/ethnicity
Number of subjects: 652
Study 30256784 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of PWV in older age groups (> 60 years) with a reference population of hypertensive individuals
Number of subjects: 652
Study 30256784 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of associations between PWV or C‐SBP and markers of glucose homeostasis or CKD
Number of subjects: 652
Study 26833336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.EnvA and Ad35.Env (both administered at a dose of 5 × 10^10 viral particles)
Number of subjects: 217
Study 26833336 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous regimen of Ad26-Ad35
Number of subjects: 217
Study 26833336 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 217
Study 26833336 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline vector immunity
Number of subjects: 217